You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Optimizing Cytomegalovirus Infection Prevention for Allogenic Hematopoietic Stem Cell Transplantation Patients

  1. What is the mechanism of action of ganciclovir and valganciclovir for cytomegalovirus (CMV) prophylaxis?
    Targets pUL54 with low risk of myelotoxicity
    Targets pUL 54 with high risk of myelotoxicity
    Targets pUL56 and is nonmyelosuppressive
    Targets pUL56, with moderate to high risk of myelotoxicity